Pharsight

Ongentys generic

Ongentys is an anti-Parkinson's drug owned by Neurocrine. The drug contains the active ingredient opicapone and comes in capsule form for oral administration. This drug was first authorized for market use on 24th April 2020, and there are currently 9 patents held for Ongentys.

When will Ongentys generic be available?

Patent challenges for the Ongentys drug can be started from 2024-04-24. However, the release of Ongentys generics is not potentially expected until 27th May 2035, following the expiration of the last patent. Generally, the entry of generic competition upon patent expiry could potentially lower prices.

Ongentys uses

The active ingredient of Ongentys, opicapone, aids in the treatment of Parkinson's disease. It works by inhibiting the COMT enzyme in the periphery, in turn reducing the O-methylation of L-DOPA. It is also used as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease.

Ongentys patent expiration

Ongentys, an anti-Parkinson drug owned by Neurocrine, holds 9 patents. The last patent, titled 'Medicaments for slowing Parkinson's disease' is expected to expire on 27 May, 2035. Post this, potential Ongentys generics may enter the market. Below are the details of the patents:

Ongentys dosage

Want to ask something?